Trinity Biotech Plc ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $61.6M+8.3% YoYTTM through 31 Dec 2024
Net Income -$31.2MTTM through 31 Dec 2024
Free Cash Flow -$4.6MTTM through 31 Dec 2024
Margins
| Current | |
|---|---|
| Gross Margin | 38.6% |
| EBITDA Margin | -34.1% |
| Operating Margin | -36.1% |
| Net Margin | -50.7% |
Returns
52.0%ROE
-35.6%ROA
Balance Sheet Health
Debt / Equity-1.73x
Current Ratio1.28x
Net Debt$119.5M
Cash & Equivalents$5.2M
Quality Metrics
Piotroski F-Score3 / 9
FCF Margin-7.5%
Earnings-Beat Rate66.7%
Multi-Year Trend
RevenueFY2024: $61.6M
Diluted EPSFY2024: $-0.09
Dividend
No dividend
Capital Allocation
Capex Intensity0.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Point-of-Care | $8.1M | -53.4% | View detailsPoint-of-care revenues declined primarily driven by reductions in HIV sales as a result of disruption to the international funding landscape for global health Rapid HIV testing in the earlier part of 2025, and the fine-tuning of manufacturing and supply-chain processes to accommodate the rise in demand for TrinScreen HIV in late 2025. |
| Haemoglobin | $16.9M | -15.9% | View detailsHaemoglobin revenues decreased partly driven by temporary manufacturing disruption during the planned transition of production under the Group's Comprehensive Transformation Plan. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.